

# Contents

---

<i>List of contributors</i>	vii
<i>Acknowledgements</i>	xiii
1 Introduction: international entrepreneurship in the life sciences <i>Marian V. Jones, Colin Wheeler and Pavlos Dimitratos</i>	1
<b>PART I NEW VENTURE ATTRIBUTES AND DEVELOPMENT CAPABILITIES</b>	
2 Assessing the internationalization capabilities of life science new ventures <i>Marian V. Jones, Colin Wheeler, Pavlos Dimitratos and George Vlachos</i>	21
3 Differences in the strategic orientations of Nordic and US-based young biotechnology ventures <i>Maija Renko</i>	39
4 Small pharmaceutical firms building capabilities to compete along the global research and development pipeline <i>Lisette Pregelj, Martie-Louise Verreynne and Damian Hine</i>	64
<b>PART II THE ROLE AND ESTABLISHMENT OF PARTNERSHIPS</b>	
5 Partnership formation in small biotech companies <i>Niina Nummela and Outi Nurminen</i>	101
6 Collaborative entrepreneurship and internationalization in life sciences: global growth through collaboration in Italian biotech firms <i>Antonella Zucchella and Diala Kabbara</i>	122
7 Alliance-driven governance in the Scottish life sciences and its contribution to regional development <i>Kean Birch and Andrew Cumbers</i>	139

**PART III DEVELOPING CAPABILITIES AND  
COMPETENCIES FOR  
INTERNATIONALIZATION**

- 8 Sub-suppliers in the life science industry: the case of two Danish university spin-offs 159  
*Erik S. Rasmussen, Martin Hannibal, René Lydixsen and Per Servais*
- 9 Rapid internationalization and sustained competitive advantage in US and UK life science international new ventures: a resource-based view 175  
*Karl Warner and Jon Carrick*
- 10 Intellectual property protection: the case of three Swiss life science SMEs 194  
*Marcus Matthias Keupp, Sascha Friesike and Oliver Gassmann*

**PART IV GROWTH, PERFORMANCE AND  
INTERNATIONALIZATION**

- 11 Performance trade-offs: success, revenue and profitability 213  
*Colin Wheeler, Marian V. Jones, George Vlachos and Pavlos Dimitratos*
- 12 Internationalization of life science firms: dynamics in the interaction between networks, innovation and export performance 227  
*Vandana Ujjual*
- 13 Firm growth and performance in biotechnology: financial facts or wishful thinking? 243  
*Malin Brännback, Alan L. Carsrud and Niklas Kiviluoto*
- 14 A model of decision-making processes in internationalized life science firms 255  
*Pavlos Dimitratos, Marian V. Jones and Colin Wheeler*
- 15 Towards a research agenda for international entrepreneurship in the life sciences 268  
*Marian V. Jones, Colin Wheeler and Pavlos Dimitratos*
- References* 286
- Index* 333